We have given out 15 winners with our stock of the week-- can we get 16!! Our only loser was FLNC which roared right back and became a winner. > Our only other loser was so far back the STOCK OF THE WEEK hadn't been coined yet-- that was ALIGN which was for sure a loser we quickly sold. 15-1
Once again to any of the viewers of which we have more than any other stock thread if anyone has learned enough to start speaking up--- the time is now. WHY DON'T WE DO THIS: 2024 IDEAS: GIVE ME 3! LETS GET SOME GOOD BUYS FOR THE NEW YEAR SO WE CAN DISH ON THEM AND SELECT THE TRULY GREAT ONES. BY THIS TIME.. AFTER ALL I HAVE DONE FOR YOU ALL-- THERE REALLY IS NO EXCUSE. LETS GET MORE INTERACTIVE-- // I CANNOT KEEP GOING AT THIS RATE. I AM RUNNING OUT OF FUNDS.
GBA right on target-! 4,888 Sun, December 10, 2023, 8:00 PM EST- (Bloomberg) — The S&P 500 Index will hit a record high in 2024 as the US avoids sinking into a recession, although a weaker consumer will mean the index gains less than this year’s 20% surge, according to Bloomberg’s latest Markets Live Pulse survey. A median of 518 respondents expect the S&P 500 to climb to 4,808 points next year — topping its previous closing peak of 4,797 hit in January 2022 — and the 10-year Treasury yield to drop to 3.8% from this year’s high of 5%.
Lets take that apart: prior high 4,797 predicted close 4,888 SELL AT THE PRIOR HIGH IF YOU KNOW WHAT IS GOOD FOR YOU.... WE ARE TALKING 100 S&P points
Ok where are we now: DAY 11 of the CRAMER CORRECTION--! I am not watching his drivel but if anyone sees Jimbo get bullish please tell me!!!
Sticking around a whole year for 4% ? Moreover, the median forecast in the survey — while a record closing high — represents a gain of just about 4% from the S&P 500’s current levels. That’s well below an average 19% jump recorded in a year in which the index advances, according to data compiled by Bloomberg. The level is also below an intraday all-time peak of 4,819.<---- Write that down!
Hottest Job in US Pays $80,000 a Year, No College Degree Needed Wind turbine technicians are in high demand, even with the recent cancellations of offshore projects.
How About a delectable GUMMY this morning-- Company Profile Minim, Inc., together with its subsidiaries, designs, manufacture, and sells and Internet access products in North America and internationally. It offers hardware products, including cable modems, cable modem/routers, gateways, mobile broadband modems, wireless routers, multimedia over coax adapters, mesh home networking devices, and other local area network products. The company also provides Minim mobile applications for end users to personalize and monitor their home and office network for speed testing, data usage tracking, security alerts, malware blocking, privacy settings, and parental controls; and Minim web application that enables technical support representatives of Internet Service Providers (ISPs) and businesses to offer remote support with network insights. In addition, it offers Minim API suite and MinimOS for third-party hardware vendors, ISPs, and other partners to integrate with the Minim platform and functionality; to manage their own account data; and to integrate with third-party router firmware. The company offers its products under the ZOOM, Motorola, and Minim brands. It sells its products through direct sales force and commissioned independent sales representatives to retailers; and retailers, distributors, ISPs, individual businesses, service providers, value-added resellers, PC system integrators, original equipment manufacturers, channel resellers, electronics distributors, and e-commerce platforms. The company was formerly known as ZoomTelephonics, Inc. and changed its name to Minim, Inc. in June 2021. Minim, Inc. was incorporated in 1977 and is headquartered in Manchester, New Hampshire. MINM Minim, Inc.@$3.20 $3.12-0.01(-0.32%)3:59 PM 12/08/23 NASDAQ |$USD |Pre-Market:$3.17+0.05(+1.60%)<--- gobble gobble Minim insider buys stock worth $1.12M SA NewsToday, 7:24 AM
Department store stocks rally after Macy's attracts a buyout offer AbbVie-Genmab lymphoma drug shows strong response rate in ongoing trial